Most non-small cell lung cancers (NSCLCs) with activating mutations in epidermal growth factor receptor (EGFR) respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Here, EGFR is linked to non-small cell lung carcinoma.